Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, April 10, 2025, at 12:45 p.m. Eastern Time.
The presentation will be accessible through a live audio webcast available on the Investor Relations section of Immunome's website. Following the live presentation, a replay will remain available for approximately 30 days.
Immunome (Nasdaq: IMNM), un'azienda biotecnologica specializzata in terapie mirate per il cancro, ha annunciato la sua prossima partecipazione alla 24ª Conferenza Sanitaria Virtuale Annuale di Needham. La direzione dell'azienda parteciperà a una chat informale programmata per giovedì 10 aprile 2025, alle 12:45 ora orientale.
La presentazione sarà accessibile tramite un webcast audio dal vivo disponibile nella sezione Relazioni con gli Investitori del sito web di Immunome. Dopo la presentazione dal vivo, una registrazione rimarrà disponibile per circa 30 giorni.
Immunome (Nasdaq: IMNM), una empresa biotecnológica especializada en terapias dirigidas contra el cáncer, ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La dirección de la empresa participará en una charla informal programada para el jueves 10 de abril de 2025, a las 12:45 p.m. hora del Este.
La presentación será accesible a través de una transmisión de audio en vivo disponible en la sección de Relaciones con Inversores del sito web de Immunome. Después de la presentación en vivo, se mantendrá una repetición disponible durante aproximadamente 30 días.
Immunome (Nasdaq: IMNM), 표적 암 치료에 특화된 생명공학 회사가 제24회 니드햄 가상 헬스케어 컨퍼런스에 참가할 예정이라고 발표했습니다. 회사 경영진은 2025년 4월 10일 목요일, 동부 표준시 기준 오후 12시 45분에 예정된 화상 대담에 참여할 것입니다.
프레젠테이션은 Immunome의 웹사이트 투자자 관계 섹션을 통해 실시간 오디오 웹캐스트로 접근할 수 있습니다. 라이브 프레젠테이션 후에는 약 30일 동안 재생이 가능할 것입니다.
Immunome (Nasdaq: IMNM), une entreprise de biotechnologie spécialisée dans les thérapies ciblées contre le cancer, a annoncé sa prochaine participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. La direction de l'entreprise participera à une discussion informelle prévue pour jeudi 10 avril 2025 à 12h45, heure de l'Est.
La présentation sera accessible via un webinaire audio en direct disponible dans la section Relations Investisseurs du site web d'Immunome. Après la présentation en direct, un replay sera disponible pendant environ 30 jours.
Immunome (Nasdaq: IMNM), ein biotechnologisches Unternehmen, das sich auf gezielte Krebstherapien spezialisiert hat, hat seine bevorstehende Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Donnerstag, den 10. April 2025, um 12:45 Uhr Eastern Time geplant ist.
Die Präsentation wird über einen Live-Audio-Webcast zugänglich sein, der im Bereich Investor Relations auf der Website von Immunome verfügbar ist. Nach der Live-Präsentation wird eine Wiederholung für etwa 30 Tage verfügbar bleiben.
- None.
- None.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which is the subject of a recently submitted IND. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404736622/en/
Investor Contact:
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
When is Immunome (IMNM) presenting at the Needham Healthcare Conference 2025?
How can investors access Immunome's (IMNM) Needham Conference presentation?
How long will the replay of Immunome's (IMNM) Needham Conference presentation be available?
What type of presentation will Immunome (IMNM) give at the Needham Healthcare Conference?
